Conference talk: Personalized Cancer Vaccines: Targeting tumor-derived neo-epitopes
Targeting the immune system with checkpoint inhibitors (CPIs) alone is not enough to drive clinical benefit for most solid tumor patients who lack neoantigen-specific T cells. Combining neoantigen immunization with CPIs may improve benefit, and Gritstone has developed a unique, potent platform for delivering antigens to the immune system to drive strong T cell responses. Our ongoing Phase 1 dose escalation study to assess safety and immunogenicity is showing early signs of clinical benefit through prolonged disease-free period and reductions in tumor lesions in some patients. Gritstone’s vaccine induces strong, durable CD8 T cell responses that can be detected in the tumor and is well tolerated with TRAEs indicative of an immune response to the vaccine.